Skip to content

Study · Animal study (in vivo) · rat · 1983

4 results

Dermorphin: an opioid peptide from amphibian skin which affects endocrine pancreatic function.

Güllner HG, Owen WW, Harris V, Unger RH

Archives internationales de pharmacodynamie et de therapie1 Nov 1983

PMID6141770 (opens in a new tab)PepBankPUB-06141770
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, dermorphin did not affect plasma insulin.

    In plain wordsIn rats, dermorphin did not change blood insulin.

    Peptide
    Dermorphin
    Outcome
    No significant changePlasma insulin
    Study

    ratn: not reported in source

    endocrine pancreatic function
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.1 to 10 micrograms per animal · intravenous injectionAs given in this study (rat).

    Source sentences

    Summary
    Dermorphin in doses ranging from 0.1 to 10 micrograms per animal did not affect plasma insulin or somatostatin-like immunoreactivity (SLI).
    1 context sentence
    Summary · context
    We examined the effect of intravenous injection of the amphibian skin opioid heptapeptide dermorphin on plasma glucose, insulin, glucagon and somatostatin in the rat.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, dermorphin did not affect plasma somatostatin-like immunoreactivity.

    In plain wordsIn rats, dermorphin did not change blood somatostatin-like immunoreactivity.

    Peptide
    Dermorphin
    Outcome
    No significant changePlasma somatostatin-like immunoreactivity
    Study

    ratn: not reported in source

    endocrine pancreatic function
    Outcome group
    Endogenous peptide levels · Endocrine and hormones
    Studied dose
    0.1 to 10 micrograms per animal · intravenous injectionAs given in this study (rat).

    Source sentences

    Summary
    Dermorphin in doses ranging from 0.1 to 10 micrograms per animal did not affect plasma insulin or somatostatin-like immunoreactivity (SLI).
    1 context sentence
    Summary · context
    We examined the effect of intravenous injection of the amphibian skin opioid heptapeptide dermorphin on plasma glucose, insulin, glucagon and somatostatin in the rat.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, dermorphin significantly increased plasma glucagon at 10 and 30 min after injection.

    In plain wordsIn rats, dermorphin increased blood glucagon at 10 and 30 min after injection.

    Peptide
    Dermorphin
    Outcome
    IncreasePlasma glucagon
    Study

    ratn: not reported in source

    endocrine pancreatic function
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.1 to 10 micrograms per animal · intravenous injectionAs given in this study (rat).

    Source sentences

    Summary
    In contrast, the opiate peptide significantly stimulated plasma glucagon and decreased plasma glucose, both 10 and 30 min following injection.
    1 context sentence
    Summary · context
    We examined the effect of intravenous injection of the amphibian skin opioid heptapeptide dermorphin on plasma glucose, insulin, glucagon and somatostatin in the rat.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, dermorphin decreased plasma glucose at 10 and 30 min after injection.

    In plain wordsIn rats, dermorphin decreased blood glucose at 10 and 30 min after injection.

    Peptide
    Dermorphin
    Outcome
    DecreasePlasma glucose
    Study

    ratn: not reported in source

    endocrine pancreatic function
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.1 to 10 micrograms per animal · intravenous injectionAs given in this study (rat).

    Source sentences

    Summary
    In contrast, the opiate peptide significantly stimulated plasma glucagon and decreased plasma glucose, both 10 and 30 min following injection.
    1 context sentence
    Summary · context
    We examined the effect of intravenous injection of the amphibian skin opioid heptapeptide dermorphin on plasma glucose, insulin, glucagon and somatostatin in the rat.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.